Resistance mutation info of drug
| Drug General Information | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug ID | D0K0YC | ||||||||||
| Drug Name | PD-0325901 | ||||||||||
| Synonyms | PD 0325901; PD 325901; PD0325901; PD325901; PD-325901; S06-0029; N-[((R)-2,3-dihydroxypropyl)oxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide; N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodo-phenyl)amino]benzamide; N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide | ||||||||||
| Drug Type | Small molecular drug | ||||||||||
| Therapeutic Class | Anticancer Agents | ||||||||||
| Company | Pfizer | ||||||||||
| Structure |
|
||||||||||
| Drug Resistance Mutations | |||||||||||
| Target Name | Dual specificity mitogen-activated protein kinase kinase 2 (MAP2K2) | Target Info | |||||||||
| Gene Name | MAP2K2 | ||||||||||
| Uniprot ID | MP2K2_HUMAN | ||||||||||
| Species | Homo sapiens | ||||||||||
| Reference Sequence |
MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQKKRLEAFLTQ KAKVGELKDDDFERISELGAGNGGVVTKVQHRPSGLIMARKLIHLEIKPAIRNQIIRELQ VLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKEAKRIPEEILGKVSIAVLRG LAYLREKHQIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMAPERLQ GTHYSVQSDIWSMGLSLVELAVGRYPIPPPDAKELEAIFGRPVVDGEEGEPHSISPRPRP PGRPVSGHGMDSRPAMAIFELLDYIVNEPPPKLPNGVFTPDFQEFVNKCLIKNPAERADL KMLTNHTFIKRSEVEEVDFAGWLCKTLRLNQPGTPTRTAV [Homo sapiens] |
||||||||||
| Targeted Disease | Lung cancer | ||||||||||
| Drug Resistance Mutations |
|
||||||||||
| Target Name | Dual specificity mitogen-activated protein kinase kinase 1 (MAP2K1) | Target Info | |||||||||
| Gene Name | MAP2K1 | ||||||||||
| Uniprot ID | MP2K1_HUMAN | ||||||||||
| Species | Homo sapiens | ||||||||||
| Reference Sequence |
MPKKKPTPIQLNPAPDGSAVNGTSSAETNLEALQKKLEELELDEQQRKRLEAFLTQKQKV GELKDDDFEKISELGAGNGGVVFKVSHKPSGLVMARKLIHLEIKPAIRNQIIRELQVLHE CNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKKAGRIPEQILGKVSIAVIKGLTYL REKHKIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMSPERLQGTHY SVQSDIWSMGLSLVEMAVGRYPIPPPDAKELELMFGCQVEGDAAETPPRPRTPGRPLSSY GMDSRPPMAIFELLDYIVNEPPPKLPSGVFSLEFQDFVNKCLIKNPAERADLKQLMVHAF IKRSDAEEVDFAGWLCSTIGLNQPSTPTHAAGV [Homo sapiens] |
||||||||||
| Targeted Disease | Lung cancer | ||||||||||
| Drug Resistance Mutations |
|
||||||||||
|
|||||||||||
| References | |||||||||||
| REF 1 | ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol Cancer Ther. 2012 May;11(5):1143-54. | ||||||||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.